ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer

European Journal of Cancer

Volumn 31, Issue 7-8, 1995, Pages 1277-1282

  Jackman, A L ^a   Farrugia, D C ^a   Gibson, W ^a   Kimbell, R ^a   Harrap, K R ^a   Stephens, T C ^b   Azab, M ^b   Boyle, F T ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

polyglutamation; thymidylate synthase; ZD1694

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; ENZYME INHIBITOR; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; POLYGLUTAMIC ACID; RALTITREXED; THYMIDYLATE SYNTHASE;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; HUMAN; MICE; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0029164564     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00166-G     Document Type: Article

References (30)

1. Thymidylate synthase inhibitors: experimental and clinical aspects
2. Preclinical and clinical aspects of biomodulation of 5-fluorouracil
3. Improvement in fluorouracil chemotherapy
4. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer
5. Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma
6. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
7. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study
8. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice
9. The history of the development and clinical use of CB3717 and ICI D1694
10. Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency
11. 10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo
12. Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position
13. 10-propargyl-5,8-dideazafolic acid (ICI 198583)
14. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study
15. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor, ZD1694 (Tomudex) in one mouse and three human cell lines
16. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells
17. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694
18. The duration of the inhibition of thymidylate synthase in intact L1210 cells exposed to different classes of quinazoline analogues
19. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB 3717
20. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells
21. The pharmacokinetics of the quinazoline antifolate ICI D1694 in mice and rats
22. Polyglutamation of the thymidylate synthase inhibitor, ZD1694 (Tomudex), in normal mouse tissues
23. ZD1694 (Tomudex) and polyglutamate levels in mouse plasma and tissues measured by radioimmunoassay and the effect of leucovorin
24. ICI D1694, an inhibitor of thymidylate synthase for clinical study
25. The thymidylate synthase inhibitor ICI D1694 is superior to CB3717, 5-fluorouracil and methotrexate against a panel of human tumour xenografts
26. The toxicity of ICI D1694 in man and mouse
27. Delayed rescue of ZD1694 toxicity in Balb/c mice with thymidine or leucovorin
28. Phase I study of the new thymidylate synthase inhibitor Tomudex (ZD1694) in patients with advanced malignancy
29. Tomudex: a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours
30. Tomudex (ZD1694), a new active agent in the treatment of advanced colorectal cancer